Abstract
Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported. Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known about the correlation between vitamin D status and prognosis in these patients.Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma who were treated at Siteman Cancer Center. Patients' demographic information, clinical staging at the time of vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25(OH)D level of between 20 ng/mL and 30 ng/mL.Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49%) had vitamin D deficiency, and 44 (25%) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic adenocarcinoma, and its effects should be further examined in a prospective study.
| Original language | English (US) |
|---|---|
| Article number | 206 |
| Journal | Journal of Translational Medicine |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| State | Published - Sep 8 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- Pancreatic cancer
- Prognostic factors
- Vitamin D
- Vitamin D receptor
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. / Cho, May; Peddi, Parvin F.; Ding, Kevin; Chen, Ling; Thomas, Denise; Wang, Jian; Lockhart, Albert C.; Tan, Benjamin; Wang-Gillam, Andrea.
In: Journal of Translational Medicine, Vol. 11, No. 1, 206, 08.09.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma
AU - Cho, May
AU - Peddi, Parvin F.
AU - Ding, Kevin
AU - Chen, Ling
AU - Thomas, Denise
AU - Wang, Jian
AU - Lockhart, Albert C.
AU - Tan, Benjamin
AU - Wang-Gillam, Andrea
PY - 2013/9/8
Y1 - 2013/9/8
N2 - Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported. Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known about the correlation between vitamin D status and prognosis in these patients.Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma who were treated at Siteman Cancer Center. Patients' demographic information, clinical staging at the time of vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25(OH)D level of between 20 ng/mL and 30 ng/mL.Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49%) had vitamin D deficiency, and 44 (25%) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic adenocarcinoma, and its effects should be further examined in a prospective study.
AB - Background: The prevalence of vitamin D deficiency among patients with cancer has been previously reported. Because vitamin D is fat soluble, patients with pancreatic adenocarcinoma may have an especially high risk of vitamin D deficiency in association with ongoing and varying degrees of malabsorption. However, little is known about the correlation between vitamin D status and prognosis in these patients.Methods: We conducted a retrospective review of vitamin D status in patients with pancreatic adenocarcinoma who were treated at Siteman Cancer Center. Patients' demographic information, clinical staging at the time of vitamin D assessment, vitamin D levels, and survival data were collected. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 20 ng/mL, and vitamin D insufficiency was defined as a 25(OH)D level of between 20 ng/mL and 30 ng/mL.Results: Between December 2007 and June 2011, 178 patients with pancreatic adenocarcinoma had their vitamin D levels checked at the time of initial visit at this center. Of these 178 patients, 87 (49%) had vitamin D deficiency, and 44 (25%) had vitamin D insufficiency. The median 25(OH)D level was significantly lower among nonwhite patients and among patients with stage I and II disease. A 25(OH)D level of less than 20 ng/mL was found to be associated with poor prognosis (p = 0.0019) in patients with stage III and IV disease.Conclusions: Vitamin D insufficiency and deficiency were prevalent among patients with pancreatic adenocarcinoma. The vitamin D level appears to be prognostic for patients with advanced pancreatic adenocarcinoma, and its effects should be further examined in a prospective study.
KW - Pancreatic cancer
KW - Prognostic factors
KW - Vitamin D
KW - Vitamin D receptor
UR - http://www.scopus.com/inward/record.url?scp=84883509784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883509784&partnerID=8YFLogxK
U2 - 10.1186/1479-5876-11-206
DO - 10.1186/1479-5876-11-206
M3 - Article
VL - 11
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
IS - 1
M1 - 206
ER -